C
2.82
-0.43 (-13.23%)
| Previous Close | 3.25 |
| Open | 3.12 |
| Volume | 596,834 |
| Avg. Volume (3M) | 1,159,929 |
| Market Cap | 201,777,760 |
| Price / Earnings (Forward) | 37.45 |
| Price / Book | 4.52 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.380 |
| Total Debt/Equity (MRQ) | 10.66% |
| Current Ratio (MRQ) | 0.360 |
| Levered Free Cash Flow (TTM) | -1.26 M |
| Return on Assets (TTM) | -22.41% |
| Return on Equity (TTM) | -93.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Citius Oncology, Inc. | Mixed | - |
AIStockmoo Score
-0.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | -0.38 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 86.80% |
| % Held by Institutions | 0.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |